QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR

Company on Track to Initiate Phase 1 Study by EOY 2009

SYDNEY and BEDMINSTER, N.J., Oct. 12 /PRNewswire-FirstCall/ -- QRxPharma
Limited (ASX: QRX and OTCQX: QRXPY) announced today a contractual agreement
with Patheon to manufacture clinical supplies of QRxPharma's controlled
release Dual-Opioid(TM) formulation (MoxDuo(TM)CR). MoxDuo(TM)CR is designed
to provide 12 hours of pain relief in patients suffering from moderate to
severe chronic pain (including cancer, lower back, osteoarthritis and
neuropathic).

"The Patheon relationship represents a major step forward for QRxPharma that
rounds out our platform of MoxDuo(TM) products," said Dr. John Holaday,
Managing Director and Chief Executive Officer. "Patheon is a well-known
manufacturing organisation with proven ability to develop novel formulations
of drugs that address global markets. Our goal is to provide physicians and
patients with a variety of complementary Dual Opioids(TM) for managing
moderate to severe pain. MoxDuo(TM)CR is expected to deliver clinical benefits
similar to those clinically demonstrated with MoxDuo(TM)IR (immediate release
formulation) - fewer side effects and superior pain relief."

The new formulation includes tamper resistant features and is designed to
provide 12 hours of pain relief. "We are targeting a twice daily dosage with
MoxDuo(TM) CR, and we anticipate our initial Phase 1 studies will begin this
year to evaluate the pharmacokinetic profile of this patented formulation,"
said Holaday. "QRxPharma's most advanced product for treating acute pain,
MoxDuo(TM)IR, is now in Phase 3 trials and scheduled for New Drug Application
(NDA) filing with the US Food and Drug Administration in 2010. QRxPharma's
formulation of MoxDuo(TM)CR is anticipated to complete clinical trials in
2012."

The Company's MoxDuo product portfolio includes immediate release, controlled
release and intravenous formulations to address pain management in hospitals
and at home. The goal is to significantly improve patient care, providing
equal or better analgesia with fewer and/or less intense side effects than
current standards of care.

"We are pleased to announce this manufacturing agreement with QRxPharma for
MoxDuo(TM)CR; we are making significant progress with clinical formulations of
this unique Dual-Opioid(TM) product," said Wes Wheeler, CEO of Patheon.

"With this agreement, the development of MoxDuo(TM)CR sets the stage to
complete the MoxDuo(TM) product portfolio for managing moderate to severe pain
in patients dealing with acute and chronic medical problems," Holaday said.

Forward Looking Statements

This press release contains forward-looking statements that involve risks and
uncertainties. The forward-looking statements contained herein represent the
judgment of QRxPharma as of the date of this release. These forward-looking
statements are not guarantees for future performance. Actual results could
differ materially from those currently anticipated due to a number of factors
including risks relating to the stage of products under development;
uncertainties relating to clinical trials; dependence on third parties; future
capital needs; and risks relating to the commercialisation of the Company's
proposed products.

About QRxPharma

QRxPharma (ASX: QRX and OTCQX: QRXPY) is a clinical-stage specialty
pharmaceutical company focused on the development and commercialisation of
therapies for pain management and central nervous system (CNS) disorders.
Based on a business strategy to expand the clinical utility and commercial
value of marketed and/or existing compounds, QRxPharma's product portfolio
includes both late and early stage clinical drug candidates with well-defined
paths to regulatory approval and sales. The Company intends to directly
commercialise its products in the US and seek strategic partnerships for
worldwide markets. QRxPharma's lead compound, MoxDuo(TM)IR (Q8003IR), is in
Phase 3 clinical development and has successfully completed multiple
comparative studies evaluating its efficacy and safety against equianalgesic
doses of morphine, oxycodone and Percocet® for the treatment of acute pain.
Study results consistently demonstrate MoxDuo(TM)IR's greater overall
tolerability, achieving better pain relief with substantially fewer incidences
of moderate to severe side effects. The Company's preclinical and clinical
pipeline includes other technologies in the fields of pain management,
neurodegenerative disease and venomics. For more information:
www.QRxPharma.com.

About Patheon:

Patheon is a leading global provider of contract dosage form development and
manufacturing services to the pharmaceutical and biotechnology industries.
Employing more than 4,700 highly-skilled staff, Patheon's network of modern
manufacturing facilities located in North America and Europe offer more than
three million square feet (300,000 m2) of best in class capacity. With three
facilities in the United States, three in Canada and four in Europe (including
two in Italy, one in France and one in the United Kingdom) Patheon is able to
meet the international requirements of its customers. Patheon's development
and manufacturing capabilities cover prescription (Rx) products in solid,
semi-solid and liquid dosage forms, as well as specialised capabilities in
high-potency, cephalosporin, controlled/sustained release and sterile
manufacturing, including aseptic filling and lyophilisation. Founded in 1974
and publicly traded since 1993 (TSX: PTI) Patheon has always been exclusively
focused on outsourcing. Patheon proudly serves more than 270 customers
including many of the world's leading pharmaceutical, biotechnology and
specialty pharmaceutical companies. For more information: www.patheon.com

SOURCE QRxPharma Limited

Chris J Campbell, Chief Financial Officer and Company Secretary, +61 2 9492
8021, chris.campbell@qrxpharma.com, or John Holaday, Ph.D., Managing Director
and Chief Executive Officer, +1-301-908-3086, john.holaday@qrxpharma.com, both
for QRxPharma Limited; Alicia Moran, PR Contact, +1-703-739-2424 (x110),
alicia@brightlinemedia.co, for QRxPharma Limited